07:48 AM EST, 11/25/2025 (MT Newswires) -- Kymera Therapeutics ( KYMR ) said Tuesday it recently began dosing patients for a phase 2b clinical trial evaluating KT-621 in patients with moderate to severe atopic dermatitis.

The company said it expects to report data from the 200-patient, 16-week trial by mid-2027.

The company said it previously announced it has completed dosing in a phase 1b trial of KT-621, with data to be reported next month.